Addex Therapeutics Ltd. (NASDAQ: ADXN) has received an amended Schedule 13D filing from Chief Executive Officer and board member Timothy Mark Dyer, updating his beneficial ownership in the company. The filing was submitted on August 27, 2026, following an increase in Addex’s outstanding share count.
Dyer reported beneficial ownership of 19,095,510 ordinary shares, representing approximately 8.9% of Addex’s outstanding shares. His holdings include 16,848,979 issued ordinary shares and another 2,246,531 shares that could be acquired through options exercisable within 60 days.
Dilution Changes Stake
The amendment does not appear to reflect a new purchase by Dyer. Instead, it was filed because additional shares issued by Addex diluted his ownership percentage, triggering an update to the previously reported Schedule 13D.
As of August 26, Addex had 210,292,217 ordinary shares outstanding. The increased share count caused Dyer’s reported ownership percentage to change by more than one percentage point from the figure disclosed in his earlier filing, requiring the amended disclosure.
CEO Maintains Full Voting Control
Dyer reported sole voting and dispositive power over all 19,095,510 shares included in his beneficial ownership. No shared voting or dispositive power was reported.
The filing identifies Dyer as Addex’s CEO and a member of its board of directors. His ownership has accumulated over several years through founder shares, private placements, stock-option exercises and equity compensation received for his executive service.
Long-Term Shareholding
The filing details multiple sources of Dyer’s holdings, including shares purchased with personal funds and shares received as compensation. He has also exercised stock options granted as part of his compensation as CEO.
Addex is a clinical-stage biopharmaceutical company developing small-molecule allosteric modulators for neurological disorders. The company reported its first-quarter 2026 financial results in June and continues to advance its development programs.
What Investors Should Watch
The amended filing gives investors an updated view of insider ownership following Addex’s recent share issuances. While Dyer continues to hold a significant stake, the filing primarily reflects dilution rather than a fresh insider transaction.
Investors will likely watch Addex’s upcoming financial and corporate updates for further information about its share count, financing activities and development programs. The company has scheduled publication of its 2026 half-year report for the week of September
